116 related articles for article (PubMed ID: 20679501)
1. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
2. Phase II dose escalation study of caspofungin for invasive Aspergillosis.
Cornely OA; Vehreschild JJ; Vehreschild MJ; Würthwein G; Arenz D; Schwartz S; Heussel CP; Silling G; Mahne M; Franklin J; Harnischmacher U; Wilkens A; Farowski F; Karthaus M; Lehrnbecher T; Ullmann AJ; Hallek M; Groll AH
Antimicrob Agents Chemother; 2011 Dec; 55(12):5798-803. PubMed ID: 21911573
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
Sáez-Llorens X; Macias M; Maiya P; Pineros J; Jafri HS; Chatterjee A; Ruiz G; Raghavan J; Bradshaw SK; Kartsonis NA; Sun P; Strohmaier KM; Fallon M; Bi S; Stone JA; Chow JW
Antimicrob Agents Chemother; 2009 Mar; 53(3):869-75. PubMed ID: 19075070
[TBL] [Abstract][Full Text] [Related]
6. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of caspofungin in older infants and toddlers.
Neely M; Jafri HS; Seibel N; Knapp K; Adamson PC; Bradshaw SK; Strohmaier KM; Sun P; Bi S; Dockendorf MF; Stone JA; Kartsonis NA
Antimicrob Agents Chemother; 2009 Apr; 53(4):1450-6. PubMed ID: 19114680
[TBL] [Abstract][Full Text] [Related]
10. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of caspofungin in ICU patients.
Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.
Leshinsky J; McLachlan A; Foster DJR; Norris R; Barrs VR
PLoS One; 2017; 12(6):e0178783. PubMed ID: 28575121
[TBL] [Abstract][Full Text] [Related]
13. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ; Adamson PC; Seibel NL; Flynn PM; Neely MN; Schwartz C; Shad A; Kaplan SL; Roden MM; Stone JA; Miller A; Bradshaw SK; Li SX; Sable CA; Kartsonis NA
Antimicrob Agents Chemother; 2005 Nov; 49(11):4536-45. PubMed ID: 16251293
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
Würthwein G; Cornely OA; Trame MN; Vehreschild JJ; Vehreschild MJ; Farowski F; Müller C; Boos J; Hempel G; Hallek M; Groll AH
Antimicrob Agents Chemother; 2013 Apr; 57(4):1664-71. PubMed ID: 23335740
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
17. Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA; Migoya EM; Hickey L; Winchell GA; Deutsch PJ; Ghosh K; Freeman A; Bi S; Desai R; Dilzer SC; Lasseter KC; Kraft WK; Greenberg H; Waldman SA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4306-14. PubMed ID: 15504857
[TBL] [Abstract][Full Text] [Related]
18. Low Caspofungin Exposure in Patients in Intensive Care Units.
van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
[TBL] [Abstract][Full Text] [Related]
19. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.
Li CC; Sun P; Dong Y; Bi S; Desai R; Dockendorf MF; Kartsonis NA; Ngai AL; Bradshaw S; Stone JA
Antimicrob Agents Chemother; 2011 May; 55(5):2098-105. PubMed ID: 21300834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
